In this interview we discuss prognostic models that may be able to predict disease progression in patients with chronic lymphocytic leukemia treated with the targeted agent ibrutinib.
As part of our coverage of the ASH Annual Meeting, we are discussing novel agents and strategies for relapsed/refractory Hodgkin lymphoma.
In this interview we discuss a recent report from the International Agency for Research on Cancer that evaluated the evidence linking obesity to cancer risk.
In this interview we discuss the idea of using schools to increase knowledge about skin cancer and attitudes toward sun exposure.
In this interview we discuss the different types of T-cell lymphomas and how supportive care is used in the management of these malignancies.
In this interview we discuss symptoms and prognosis for patients with polycythemia vera and essential thrombocythemia and the treatment of myelofibrosis.
In this interview we discuss the GeneFx Colon test (or the ColDx assay), which can helpful identify patients with low- or high-risk stage II colon cancer.
In this interview we discuss new consensus guidelines from ASCO, SSO, and ASTRO that establish 2 mm surgical margins for treating DCIS patients.
In this interview we discuss a recent study that identified genetic mechanisms of immunoresistance to treatment with anti-PD-1 antibodies.
In this interview we discuss the CheckMate 142 trial, which looked at nivolumab and ipilimumab for the treatment of metastatic colorectal cancer.